349 related articles for article (PubMed ID: 26927026)
1. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
3. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
4. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
5. Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
Hölsken A; Stache C; Schlaffer SM; Flitsch J; Fahlbusch R; Buchfelder M; Buslei R
Pituitary; 2014 Dec; 17(6):546-56. PubMed ID: 24356780
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation.
Hara T; Akutsu H; Takano S; Kino H; Ishikawa E; Tanaka S; Miyamoto H; Sakamoto N; Hattori K; Sakata-Yanagimoto M; Chiba S; Hiyama T; Masumoto T; Matsumura A
J Neurosurg; 2018 Aug; 131(1):217-226. PubMed ID: 30074466
[TBL] [Abstract][Full Text] [Related]
7. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
8. A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
Burghaus S; Hölsken A; Buchfelder M; Fahlbusch R; Riederer BM; Hans V; Blümcke I; Buslei R
Virchows Arch; 2010 Mar; 456(3):287-300. PubMed ID: 20069432
[TBL] [Abstract][Full Text] [Related]
9. Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.
Stache C; Hölsken A; Fahlbusch R; Flitsch J; Schlaffer SM; Buchfelder M; Buslei R
Neuro Oncol; 2014 Jan; 16(2):256-64. PubMed ID: 24305709
[TBL] [Abstract][Full Text] [Related]
10. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
12. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
14. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
15. EGFR signaling regulates tumor cell migration in craniopharyngiomas.
Hölsken A; Gebhardt M; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Clin Cancer Res; 2011 Jul; 17(13):4367-77. PubMed ID: 21562037
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
17. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
[TBL] [Abstract][Full Text] [Related]
18. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
19. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
20. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
